Immune Response Corp. has filed for a public offering of 2.2million shares of common stock. Following successfulcompletion of the offering, Immune Response will have 13.2million shares of common stock outstanding.
The company, based in San Diego, said it will use the proceedsto continue development of its pharmaceutical products.
Underwriters Montgomery Securities and Robertson, Stephens& Co., both of San Francisco, have options to purchase anadditional 330,000 shares through an overallotment.
Immune Response stock (NASDAQ:IMNR) closed at $8.88 onTuesday, down 33 cents.
Ref: BioWorld, 04/10/91, Vol. 3 No. 70
(c) 1997 American Health Consultants. All rights reserved.